Expert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung Cance

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistancePerforming biomarker testing on cytology vs surgical or anatomic pathology specimensFactors affecting turnaround time when testing liquid biopsy vs tissue specimensChoice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skippingConcordance between IHC and FISH or NGS for ALK rearrangementsUse of fluid cytology specimens when testing for fusions in RET or NTRK and MET amplificationCost considerations with performing multiple single-gene assays vs upfront NGSTesting for driver mutations in early-stage NSCLCDeveloping institutional workflows to enable pathologists to order reflex molecular testing panelsPresenters:Nathan Pennell, MD, PhDProfessorDirector, Cleveland Clinic Lung Cancer Medical Oncology ProgramDepartment of Hematology and Medical OncologyCleveland Clinic Taussig Cancer InstituteCleveland, OhioLaura J. Tafe, MDAssociate Professor of Pathology and Laboratory MedicineDartmouth-Hitchcock Medical CenterLebanon, New HampshireThe Geisel School of Medicine at DartmouthHanover, New HampshireContent supported by an educational grant from Lilly.Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:http://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.